Holen Sie sich die Stockscreener-App
140.33
0.49%
-0.69
Handel nachbörslich:
139.86
-0.47
-0.33%
Schlusskurs vom Vortag:
$141.02
Offen:
$140.2
24-Stunden-Volumen:
3.08M
Relative Volume:
1.46
Marktkapitalisierung:
$24.28B
Einnahmen:
$15.50B
Nettoeinkommen (Verlust:
$1.33B
KGV:
19.12
EPS:
7.34
Netto-Cashflow:
$2.16B
1W Leistung:
+2.43%
1M Leistung:
-8.55%
6M Leistung:
-30.13%
1J Leistung:
-36.92%
1-Tages-Spanne:
$137.33
$141.33
1-Wochen-Bereich:
$137.33
$141.95
52-Wochen-Spanne:
$134.65
$252.88
Iqvia Holdings Inc Stock (IQV) Company Profile
Firmenname
Iqvia Holdings Inc
Sektor
Branche
Telefon
919-998-2000
Adresse
2400 ELLIS ROAD, DURHAM, NC
Vergleichen Sie IQV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-13 | Eingeleitet | BTIG Research | Buy |
| 2023-11-02 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-03-17 | Eingeleitet | Truist | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-11-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-15 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-16 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-03-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2020-07-07 | Eingeleitet | Stephens | Equal-Weight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Hochstufung | CFRA | Sell → Hold |
| 2019-11-14 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-06-21 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-05-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-10-02 | Bestätigt | Robert W. Baird | Outperform |
| 2018-07-25 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-07-25 | Bestätigt | Stifel | Buy |
| 2018-07-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-04-13 | Hochstufung | Goldman | Neutral → Buy |
| 2018-03-07 | Hochstufung | SunTrust | Hold → Buy |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Iqvia Holdings Inc Aktie (IQV) Neueste Nachrichten
IQVIA Holdings Inc (IQV) Trading 3.28% Higher on May 27 - GuruFocus
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf - marketscreener.com
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV S - GuruFocus
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV Stock News - GuruFocus
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com
IQVIA’s SWOT analysis: healthcare data giant faces industry headwinds - Investing.com Australia
IQVIA’s SWOT analysis: healthcare data giant faces industry headwinds By Investing.com - Investing.com Nigeria
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? - MSN
IQVIA (IQV) Projects Global Cancer Drug Spending to Hit $441B by 2029 - GuruFocus
(IQV) Trading Advice - news.stocktradersdaily.com
IQV: Cautious Outlook Amidst Delayed Decisions | IQV Stock News - GuruFocus
IQVIA Holdings Inc (IQV) Stock Price Down 3.4% on May 21 - GuruFocus
IQVIA Stock: Is Wall Street Bullish or Bearish? - Barchart.com
IQVIA (IQV) Stock Sees Analyst Target Price Adjustment by JP Mor - GuruFocus
IQVIA (IQV) Stock Sees Analyst Target Price Adjustment by JP Morgan | IQV Stock News - GuruFocus
IQV Q1 Earnings Call: Real-World Evidence Drives Outperformance Amid Sector Uncertainty - Yahoo Finance
IQVIA Holdings (NYSE:IQV) Partners With SCRI Innovations To Enhance Global Oncology Trials - Yahoo
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - marketscreener.com
IQVIA Teams Up With SCRI to Expedite Development of New Cancer Therapies - marketscreener.com
IQVIA And SCRI Collaborate To Accelerate Global Oncology Trials - marketscreener.com
Is IQVIA Holdings Inc. (IQV) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
Deep Dive Into IQVIA Hldgs Stock: Analyst Perspectives (10 Ratings) - Benzinga
IQVIA Holdings (IQV): Analyst Maintains Rating, Lowers Price Tar - GuruFocus
IQVIA Holdings (IQV): Analyst Maintains Rating, Lowers Price Target | IQV Stock News - GuruFocus
Mizuho Adjusts Price Target for Iqvia (IQV) to $190 | IQV Stock News - GuruFocus
Mizuho Adjusts Price Target on IQVIA Holdings to $190 From $210, Maintains Outperform Rating - marketscreener.com
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Questex’s Fierce Biotech Announces 2025 Fierce CRO Award Finalists - GlobeNewswire Inc.
Positive Outlook for IQVIA Holdings Driven by Resilient TAS, Strategic Capital Allocation, and R&D Strength - TipRanks
IQVIA Holdings Inc. (NYSE:IQV) Q1 2025 Earnings Call Transcript - MSN
IQVIA at BofA Securities 2025: Strong Q1 Amid Market Challenges By Investing.com - Investing.com Nigeria
IQVIA at BofA Securities 2025: Strong Q1 Amid Market Challenges - Investing.com
Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends - Yahoo Finance
(IQV) Investment Analysis and Advice - news.stocktradersdaily.com
IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates - MSN
IQVIA: Q1 Earnings Support Steady Optimism (NYSE:IQV) - Seeking Alpha
IQVIA raises 2025 revenue guidance amid strong TAS growth and expanded AI deployment - MSN
Morgan Stanley Adjusts Price Target on IQVIA Holdings to $185 From $250, Maintains Overweight Rating - marketscreener.com
Truist Financial Sticks to Its Buy Rating for IQVIA Holdings (IQV) - The Globe and Mail
IQVIA Ups Revenue Forecast After Exceeding Profit Estimates - Finimize
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13 - Business Wire
Barclays Lowers IQVIA Holdings (IQV) Price Target to $165 Amid Demand Concerns | IQV stock price - paginasiete.bo
IQVIA (IQV) Target Price Lowered by UBS, Rating Maintained | IQV Stock News - GuruFocus
IQVIA Holdings (IQV): Barclays Lowers Price Target to $165 | IQV Stock News - GuruFocus
Stephens Adjusts Price Target on IQVIA Holdings to $200 From $250, Maintains Overweight Rating - marketscreener.com
Citigroup Adjusts Price Target on IQVIA Holdings to $160 From $210, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Price Target on IQVIA Holdings to $161 From $195, Maintains Neutral Rating - marketscreener.com
Barclays Adjusts Iqvia (IQV) Price Target Amid Demand Concerns | IQV Stock News - GuruFocus
Finanzdaten der Iqvia Holdings Inc-Aktie (IQV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.51%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):